Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +7.08% | +3.63% | +45.20% |
Financials (USD)
Sales 2024 * | 9.22M | Sales 2025 * | 5.09M | Capitalization | 449M |
---|---|---|---|---|---|
Net income 2024 * | -78M | Net income 2025 * | -93M | EV / Sales 2024 * | 37.6 x |
Net cash position 2024 * | 102M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 59.9 x |
P/E ratio 2024 * |
-5.96
x | P/E ratio 2025 * |
-5.15
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.53% |
Latest transcript on Taysha Gene Therapies, Inc.
1 day | +7.08% | ||
1 week | +3.63% | ||
Current month | +5.76% | ||
1 month | -3.38% | ||
3 months | +76.03% | ||
6 months | +93.23% | ||
Current year | +45.20% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 20-07-31 |
President | 58 | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 20-08-30 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Sean Stalfort
BRD | Director/Board Member | 53 | 23-06-20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 2.57 | +7.08% | 2 700 621 |
24-05-13 | 2.4 | +2.56% | 923,238 |
24-05-10 | 2.34 | -7.51% | 1,407,720 |
24-05-09 | 2.53 | +6.30% | 1,236,896 |
24-05-08 | 2.38 | -4.03% | 1,850,885 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.20% | 449M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- TSHA Stock